Type I PRMT Inhibition for DRP Toxicity in ALS and FTD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The expansion of hexanucleotide repeats in the C9ORF72 gene leads to the formation of dipeptide repeat proteins (DRPs) that cause cellular toxicity, particularly in neuronal cells, contributing to neurodegenerative diseases like ALS and FTD, with the mechanisms of action and contributions of each DRP to neurodegeneration remaining unclear.
Innovation Solution
Inhibition of Type I protein arginine methyltransferases (PRMTs) using inhibitors such as MS023, MS049, EPZ020411, GSK715, and TP 064 to abrogate the toxic effects of DRPs, particularly glycine-arginine (GR) and proline-arginine (PR) dipeptide repeats, thereby reducing cellular toxicity and protecting neuronal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If Type I PRMT inhibitors are used to inhibit asymmetric methylation of arginine substrates in DRPs, then cellular toxicity is decreased, but the mechanism of action and contribution of each DRP to neurodegeneration remains unclear
Solution Approach 1:
The patent uses Type I PRMT inhibitors as intermediary agents to block the toxic pathway of DRP asymmetric methylation without requiring complete understanding of each individual DRP mechanism. The inhibitors serve as a mediator that interrupts the harmful process between the DRPs and cellular targets, allowing therapeutic effect while mechanism research continues independently
2Adaptability or versatility
If inhibitors target multiple Type I PRMTs (PRMT1, PRMT3, PRMT4, PRMT6, PRMT8), then broad DRP toxicity is reduced, but drug specificity and selectivity become challenging
Solution Approach 1:
The patent employs Type I PRMT inhibitors with multi-functional capability to target multiple PRMT enzymes (PRMT1, PRMT3, PRMT4, PRMT6, PRMT8) simultaneously. This universal approach allows a single inhibitor class to address broad DRP toxicity across different neuronal cell types and disease contexts, trading some enzyme-specific precision for comprehensive therapeutic coverage
3Reliability
If asymmetric methylation of arginine substrates is inhibited, then cellular dysfunction and cell death are prevented, but endogenous protein methylation may be affected
Solution Approach 1:
The patent applies local quality control by focusing inhibition specifically on asymmetric methylation of arginine substrates within dipeptide repeat proteins while attempting to preserve symmetric methylation and other endogenous protein modifications. The selective targeting of asymmetric methylation pathways in DRPs versus normal cellular proteins aims to achieve localized therapeutic effect with minimal disruption to overall cellular methylation homeostasis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of Type I PRMT inhibitors effectively decreases cellular toxicity and cell death induced by DRPs, offering a potential treatment for neurodegenerative diseases associated with DRP expression, such as ALS and FTD, by reducing asymmetric methylation of arginine substrates.
Implementation Method 1
the toxic effects caused by DRPs is driven by asymmetric methylation of the arginine substrates within the dipeptide repeats
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 3A~3D
AI summary
Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).